{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T10:22:55Z","timestamp":1648808575968},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["L'Enc\u00e9phale"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.encep.2015.03.006","type":"journal-article","created":{"date-parts":[[2016,3,31]],"date-time":"2016-03-31T06:30:02Z","timestamp":1459405802000},"page":"21-26","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["\u00c9volution de la prise en charge m\u00e9dicamenteuse de la maladie d\u2019Alzheimer en EHPAD\u00a0: impact de la campagne m\u00e9diatique contre les m\u00e9dicaments sp\u00e9cifiques de la maladie d\u2019Alzheimer"],"prefix":"10.1016","volume":"43","author":[{"given":"A.-E.","family":"Petit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Mangeard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Chazard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Puisieux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.encep.2015.03.006_bib0140","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3233\/JAD-2012-111943","article-title":"French National Alzheimer databank (BNA). The 2008\u20132012\u00a0French Alzheimer plan: description of the national Alzheimer information system","volume":"29","author":"Le Duff","year":"2012","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.encep.2015.03.006_bib0145","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000093459","article-title":"Dementia in subjects aged 75\u00a0years or over within the PAQUID cohort: prevalence and burden by severity","volume":"22","author":"Helmer","year":"2006","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.encep.2015.03.006_bib0150","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.jamda.2010.06.003","article-title":"Patterns of dementia treatment use in assisted living facilities: a cross-sectional study of 1975\u00a0demented residents","volume":"12","author":"Barro-Belaygues","year":"2011","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.encep.2015.03.006_bib0155","series-title":"Les pathologies des personnes \u00e2g\u00e9es vivant en \u00e9tablissement","author":"Dutheil","year":"2006"},{"key":"10.1016\/j.encep.2015.03.006_bib0160","first-page":"23","article-title":"Cholinergic hypothesis and Alzheimer's disease: the place of donepezil (Aricept)","volume":"5","author":"Robert","year":"1999","journal-title":"Enc\u00e9phale"},{"issue":"366","key":"10.1016\/j.encep.2015.03.006_bib0165","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1106668","article-title":"Donepezil and memantine for moderate-to-severe Alzheimer's disease","volume":"8","author":"Howard","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.encep.2015.03.006_bib0170","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1177\/0269881110387547","article-title":"Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology","volume":"25","author":"O\u2019Brien","year":"2011","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.encep.2015.03.006_bib0175","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005593","article-title":"Cholinesterase inhibitors for Alzheimer's disease","author":"Birks","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.encep.2015.03.006_bib0180","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2174\/156720511797633205","article-title":"Effects of galantamine in Alzheimer's disease: double-blind withdrawal studies evaluating sustained versus interrupted treatment","volume":"8","author":"Gaudig","year":"2011","journal-title":"Curr Alzheimer Res"},{"issue":"1","key":"10.1016\/j.encep.2015.03.006_bib0185","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0013-7006(04)95418-8","article-title":"Memantine (Ebixa): a new therapeutic strategy for the treatment of moderate to severe forms of Alzheimer's disease","volume":"30","author":"Gallarda","year":"2004","journal-title":"Enc\u00e9phale"},{"key":"10.1016\/j.encep.2015.03.006_bib0190","series-title":"Abrogation de la recommandation relative \u00e0 la prise en charge de la maladie d\u2019Alzheimer","author":"HAS","year":"2011"},{"key":"10.1016\/j.encep.2015.03.006_bib0195","series-title":"Compte rendu de la commission de la transparence du 19\u00a0octobre","author":"HAS","year":"2011"},{"key":"10.1016\/j.encep.2015.03.006_bib0200","series-title":"Maladie d\u2019Alzheimer et maladies apparent\u00e9es\u00a0: diagnostic et prise en charge. Recommandation de bonne pratique.","author":"HAS","year":"2011"},{"key":"10.1016\/j.encep.2015.03.006_bib0205","series-title":"Celtipharm, soci\u00e9t\u00e9 sp\u00e9cialis\u00e9e dans le recueil d\u2019informations sur les produits vendus en officine","year":"2013"},{"key":"10.1016\/j.encep.2015.03.006_bib0210","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s12612-009-0004-1","article-title":"Description des r\u00e9sidents d\u2019EHPA\u00a0: donn\u00e9es de l\u2019enqu\u00eate men\u00e9e par le REHPA (Recherche en \u00e9tablissements d\u2019h\u00e9bergement pour personnes \u00e2g\u00e9es)","author":"Rolland","year":"2009","journal-title":"Cah Annee Gerontol"},{"key":"10.1016\/j.encep.2015.03.006_bib0215","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/pds.3303","article-title":"Use of drug treatments for Alzheimer's disease in France: a study on a national level based on the National Alzheimer's Data Bank (Banque nationale Alzheimer)","volume":"21","author":"Tifratene","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.encep.2015.03.006_bib0220","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/WAD.0b013e31815a9e10","article-title":"Memantine therapy for Alzheimer disease in real-world practice: an observational study in a large representative sample of French patients","volume":"22","author":"Vidal","year":"2008","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"78","key":"10.1016\/j.encep.2015.03.006_bib0225","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1212\/WNL.0b013e31824d5773","article-title":"Effect of treatment gaps in a cohort of demented elderly treated with cholinesterase inhibitors","volume":"27","author":"Pariente","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.encep.2015.03.006_bib0230","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3233\/JAD-2011-110134","article-title":"Cessation versus continuation of galantamine treatment after 12\u00a0months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial","volume":"26","author":"Scarpini","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.encep.2015.03.006_bib0235","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1017\/S1041610210001535","article-title":"Discontinuing cholinesterase inhibitors: results of a survey of Canadian dementia experts","volume":"23","author":"Herrmann","year":"2011","journal-title":"Int Psychogeriatr"},{"key":"10.1016\/j.encep.2015.03.006_bib0240","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.amjopharm.2011.08.004","article-title":"Discontinuation of acetylcholinesterase inhibitor treatment in the nursing home","volume":"9","author":"Mansour","year":"2011","journal-title":"Am J Geriatr Pharmacother"},{"key":"10.1016\/j.encep.2015.03.006_bib0245","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.amjopharm.2009.04.002","article-title":"Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia","volume":"7","author":"Daiello","year":"2009","journal-title":"Am J Geriatr Pharmacother"},{"key":"10.1016\/j.encep.2015.03.006_bib0250","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ana.23557","article-title":"Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial","volume":"72","author":"Mori","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.encep.2015.03.006_bib0255","doi-asserted-by":"crossref","first-page":"6","DOI":"10.7326\/0003-4819-156-12-201206190-02010","article-title":"Donepezil or memantine improved cognitive functioning in moderate-to-severe Alzheimer disease","volume":"156","author":"Burke","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.encep.2015.03.006_bib0260","doi-asserted-by":"crossref","first-page":"899","DOI":"10.2146\/ajhp070622","article-title":"Treatment of Alzheimer's disease in the long-term-care setting","volume":"66","author":"Smith","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.encep.2015.03.006_bib0265","series-title":"Note des m\u00e9dicaments anti-Alzheimer d\u00e9grad\u00e9e. Union nationale des Associations France-Alzheimer","author":"France-Alzheimer","year":"2015"},{"key":"10.1016\/j.encep.2015.03.006_bib0135","doi-asserted-by":"crossref","first-page":"e3086","DOI":"10.1136\/bmj.e3086","article-title":"Effectiveness of dementia follow-up care by memory clinics or general practitioners: randomised controlled trial","volume":"344","author":"Meeuwsen","year":"2012","journal-title":"BMJ"}],"container-title":["L'Enc\u00e9phale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013700616000452?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013700616000452?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T00:12:26Z","timestamp":1567728746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0013700616000452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0013700616000452"],"URL":"https:\/\/doi.org\/10.1016\/j.encep.2015.03.006","relation":{},"ISSN":["0013-7006"],"issn-type":[{"value":"0013-7006","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u00c9volution de la prise en charge m\u00e9dicamenteuse de la maladie d\u2019Alzheimer en EHPAD\u00a0: impact de la campagne m\u00e9diatique contre les m\u00e9dicaments sp\u00e9cifiques de la maladie d\u2019Alzheimer","name":"articletitle","label":"Article Title"},{"value":"L'Enc\u00e9phale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.encep.2015.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 L'Enc\u00e9phale, Paris.","name":"copyright","label":"Copyright"}]}}